Tarsier Pharma
Zichron Yaacov, Israel· Est.
Innovative immunomodulator platform for ocular inflammatory diseases, advancing multiple candidates toward late‑stage trials.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Innovative immunomodulator platform for ocular inflammatory diseases, advancing multiple candidates toward late‑stage trials.
OphthalmologyImmunology
Technology Platform
Dazdotuftide (TRS) is a bio‑inspired immunomodulator that re‑engineers the ocular immune environment to control inflammation, delivered via eye drops or intravitreal injection.
Opportunities
Leverage a novel immunomodulatory platform to address large unmet needs in uveitis and related ocular inflammatory diseases, with potential expansion into dry eye, diabetic macular edema, and AMD.
Risk Factors
Clinical trial outcomes, regulatory approval timelines, and competition from established ophthalmic biologics and steroids could impact commercialization prospects.
Competitive Landscape
Competes with steroid‑based therapies and emerging biologics (e.g., anti‑TNF, anti‑IL‑6) but differentiates through a bio‑inspired, immune‑re‑engineering approach that may offer improved safety and efficacy.